Yucheng Sheng

Dec 18, 2023 | ascpt.onlinelibrary.wiley.com | Yucheng Sheng |Ltd. Shanghai |Jingru Wang |Shu-wen Teng

Overall survival is vital for approving new anticancer drugs but is often impractical for early-phase studies. The tumor growth inhibition-overall survival (TGI-OS) model could bridge the gap between early- and late-stage development. This study aimed to identify an appropriate TGI-OS model for non-small cell lung cancer (NSCLC) patients from the GEMSTONE-302 study of sugemalimab.